Please login to the form below

Not currently logged in
Email:
Password:

Neurimmune appoints chief business officer

Fabian Buller will further drive the biopharma’s growth strategy

Monoclonal antibody-focused Neurimmune has appointed Fabian Buller into the newly created role of chief business officer.

Buller joins the biopharmaceutical group’s executive team, bringing with him eight years of biotech and pharma experience.

Prior to joining Neurimmune, Buller served as director new ventures at Johnson & Johnson Innovation, as well as director of business development of Covagen.

Roger Nitsch, president and CEO of Neurimmune, said: “We are pleased that Dr Buller joins our company to further drive our growth strategy.

“Dr Buller has an impressive track record in business development and licensing transactions.

“He will play a key role in realising opportunities that will allow us to bring novel therapeutics to patients.”

2nd May 2018

From: PME

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...